<DOC>
	<DOC>NCT00305474</DOC>
	<brief_summary>This study seeks to determine whether adult, non-psychotic, first-degree relatives of schizophrenic patients who show specific neurocognitive deficits and negative symptoms will show improvements in these areas following a 6-month, double-blind trial of a low dose (up to 2.0 mg) of risperidone.</brief_summary>
	<brief_title>Identification and Treatment of the Liability to Develop Schizophrenia</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Having at least one firstdegree biological relative with schizophrenia and their age is between 19 and 59. Desire to participate in a medication trial. Is able to provide informed consent. Having moderate levels of negative symptoms, defined as 6 items rated 3 or higher on the Scale for the Assessment of Negative Symptoms (SANS). Scoring two or more standard deviations below normal in at least one of three cognitive domains: vigilance/working memory, longterm verbal memory, and executive functions. Scoring at least one standard deviation below normal in a second cognitive domain. IQ less than 80. Formal education less than 10 years. History of psychotic disorders. History of treatment with an antipsychotic medication. A substance abuse diagnosis within 6 months of diagnosis. A head injury with documented loss of consciousness exceeding 5 minutes (or subsequent cognitive deficits). A history of neurologic disease or damage. A medical condition with significant cognitive sequelae. A history of electroconvulsive treatment.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Negative symptoms</keyword>
	<keyword>neuropsychological deficits</keyword>
	<keyword>Cognitive function</keyword>
	<keyword>diagnostic</keyword>
	<keyword>prevention</keyword>
</DOC>